SSY GROUP Limited (02005) announced that its Azilsartan Medoxomil Potassium has been approved for registration by China's National Medical Products Administration as an active pharmaceutical ingredient for use in marketed drug formulations. Azilsartan Medoxomil Potassium is primarily indicated for the treatment of essential hypertension in adults.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments